regadenoson has been researched along with Heart Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amer, KA; Cohen, G; Edwin, SB; Hurren, JR | 1 |
| Gould, KL; Johnson, NP | 1 |
| Aljaroudi, W; Hage, F; Heo, J; Hermann, D; Iskandrian, AE | 1 |
| Ananthasubramaniam, K; Cabrera, R; Dhanalakota, S; Husain, Z; Jacobsen, G; Karthikeyan, AS; Palani, G; Pathmanathan, S | 1 |
| Ahmed, A; Dean, PJ; Hage, FG; Heo, J; Iqbal, FM; Iskandrian, AE; Raslan, S | 1 |
| Udelson, JE | 1 |
6 other study(ies) available for regadenoson and Heart Diseases
| Article | Year |
|---|---|
Regadenoson versus Dipyridamole: A Comparison of the Frequency of Adverse Events in Patients Undergoing Myocardial Perfusion Imaging.
Topics: Adenosine A2 Receptor Agonists; Aged; Cohort Studies; Cost-Benefit Analysis; Dipyridamole; Dyspnea; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Retrospective Studies; Vasodilator Agents | 2017 |
Regadenoson versus dipyridamole hyperemia for cardiac PET imaging.
Topics: Adenosine A2 Receptor Agonists; Adult; Aged; Dipyridamole; Female; Heart Diseases; Hemodynamics; Humans; Hyperemia; Male; Middle Aged; Positron-Emission Tomography; Purines; Pyrazoles; Vasodilator Agents | 2015 |
Safety of regadenoson in patients with end-stage renal disease.
Topics: Exercise Test; Female; Follow-Up Studies; Heart Diseases; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2010 |
Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients.
Topics: Adenosine A2 Receptor Antagonists; Aged; Asthma; Atrioventricular Block; Bronchoconstriction; Chi-Square Distribution; Female; Heart Diseases; Hemodynamics; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Organophosphorus Compounds; Organotechnetium Compounds; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Purines; Pyrazoles; Radiopharmaceuticals; Retrospective Studies; Risk Assessment; Risk Factors; Tachycardia, Supraventricular; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2012 |
Comparison of the prognostic value of normal regadenoson with normal adenosine myocardial perfusion imaging with propensity score matching.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Cause of Death; Chi-Square Distribution; Female; Heart Diseases; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Predictive Value of Tests; Prognosis; Propensity Score; Proportional Hazards Models; Purines; Pyrazoles; Reference Values; Risk Factors; Stroke Volume; Time Factors; Vasodilator Agents; Ventricular Function, Left | 2012 |
Comparing prognostic value of imaging agents and imaging techniques.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Female; Heart Diseases; Humans; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2012 |